LYEL · Lyell Immunopharma, Inc.
$15.53
+0.18 (+1.17%)
At close · Aug 21
Market Cap
$380.56M
Shares
24.51M
Share-repurchase activity from the company's own XBRL filings — cash spent buying back common stock per fiscal year and per recent quarter, share counts where the company tagged them, and the buyback program's authorization — paired with the company's at-the-market (ATM) equity offering programs, the dilution side of the same picture. Repurchase amounts come exclusively from tagged SEC data; program figures with no tagged equivalent (untagged authorizations and all ATM figures) are read from the filing's own text and shown only after verification.
Equity Offering (ATM) Programs
| Program Established | Last Amended | Capacity | Remaining | Runs Through | Source |
|---|---|---|---|---|---|
| 2024-02-28 | — | $150,000,000 | — | — | 10-Q , filed 2025-11-12 |
Repurchase History
| Fiscal Year Ended | Cash Spent | Source |
|---|---|---|
| 2022-12-31 | $0 | 10-K, filed 2023-02-28 |
| 2021-12-31 | $0 | 10-K, filed 2023-02-28 |
| 2020-12-31 | $11,806,000 | 10-K, filed 2023-02-28 |
| 2019-12-31 | $185,000 | 10-K, filed 2022-03-29 |
Key facts
CIK
1806952
CUSIP
55083R203
13F (30d)
88 filings
87 filers
Visit website
Investor relations